Last reviewed · How we verify

NCT05130853: SoCIAL

Efficacy Study of a New Individualized Rehabilitation Programme for Social Cognition in Patients With Schizophrenia

Completed NA Last updated 31 May 2023
What this trial tests

NA trial testing Social Skills and Neurocognitive Individualized Training (SoCIAL) in Schizophrenia in 48 participants. Completed in 31 July 2022.

Timeline
10 January 2021
Primary endpoint
31 July 2022
31 July 2022

Quick facts

Lead sponsorUniversity of Campania Luigi Vanvitelli
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment48
Start date10 January 2021
Primary completion31 July 2022
Estimated completion31 July 2022
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

University of Campania Luigi Vanvitelli

Who can join

Adults 18 to 50, any sex, with Schizophrenia or Schizo Affective Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients affected by schizophrenia often present significant deficits in various aspects of social cognition, such as social perception, recognition of one's own and other people's emotional state and the theory of mind. Recent studies investigated the correlation between social cognition and real-life functioning, reporting that greater social cognition deficits determine worse social and occupational functioning in real-life. Therefore, social cognition deficits represent an important target both in therapeutic and rehabilitative treatment in patients with psychotic conditions, especially in the early phases of the disease. Our research group has implemented a new individualized rehabilitation programme for social cognition: the Social Cognition Individualized Activities Lab, SoCIAL. The pivotal study showed that this programme improves specifically social cognition abilities, even when compared to a standardised and validated rehabilitation programme such as the Social Skills And Neurocognitive Individualized Training (SSANIT). However, the improvement in social cognition did not translate in improvement in real-life functioning. Recently, another key aspect that plays a role in quality of life and real life functioning in people with schizophrenia has emerged, the narrative abilities. Available data confirm that this variable has a strong impact on social functioning and quality of life in patients with schizophrenia. Taking into account the above evidence, our group decided to implement a new version of the social cognitive remediation programme in order to overcome the limitations found during its pivotal study. The new SoCIAL programme is characterized by specific modules for training of social cognition and narrative abilities in patients with schizophrenia. The efficacy of this programme, compared to treatment as usual, in individuals diagnosed with schizophrenia or schizoaffective disorder will be assessed. The generalization of improvement to real-life functioning domains will also be evaluated in completers and in the intent-to-treat sample.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Social Cognition Individualized Activities Lab for Social Cognition Training and Narrative Enhancement in Patients With Schizophrenia: A Randomized Controlled Study to Assess Efficacy and Generalization to Real-Life Functioning (Prot. n°: NCT05130853).
    Palumbo D, Caporusso E, Piegari G, Mencacci C, et al · · 2022 · cited 6× · PMID 35444577 · DOI 10.3389/fpsyt.2022.833550
  2. Effectiveness of a social cognition remediation intervention for patients with schizophrenia: a randomized-controlled study.
    Giuliani L, Pezzella P, Mucci A, Palumbo D, et al · · 2024 · cited 2× · PMID 39732701 · DOI 10.1186/s12991-024-00535-9

Verify or expand the search:

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

Other University of Campania Luigi Vanvitelli trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05130853.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing